Results 141 to 150 of about 186,128 (186)

Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study. [PDF]

Int J Retina Vitreous
Kanadani T, Rabelo N, Takahashi D, Magalhães L, Farah M.   +4 more
europepmc   +1 more source

Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy [PDF]

British Journal of Ophthalmology, 2018
AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the
Ahmad M, Mansour, Abdulrazzak, Charbaji, Michel Eid, Farah, Hana A, Mansour, Jay, Chhablani   +4 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Treat and extend protocol outcomes in diabetic macular edema: A narrative review

American Journal of Ophthalmic Clinical Trials, 2022
The objective of this study was to pool available data on change in visual acuity, number of injections, and change in central subfield thickness as reported by treat and extend (T&E) regimens for diabetic macular edema (DME) compared to monthly and pro re nata (PRN) regimens.
Param Bhatter, Abhinav Bheemidi, Justin C. Muste, Shirley Z. Wu, Molly J. E. Snider, Carolina C. S. Valentim, Rishi P. Singh   +6 more
openaire   +1 more source

TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION

Retina, 2016
To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve retinal angiomatous proliferation (RAP) and development of retinal pigment epithelium (RPE) atrophy.We retrospectively studied 17 treated eyes with RAP and 13 untreated fellow eyes.
Hidetaka, Matsumoto, Taku, Sato, Masahiro, Morimoto, Ryo, Mukai, Maki, Takahashi, Takashi, Hiroe, Kensuke, Ehara, Mayuko, Takayama, Kensuke, Mimura, Shoji, Kishi   +9 more
openaire   +2 more sources

Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial

Japanese Journal of Ophthalmology, 2021
To investigate the efficacy and safety of a treat-and-extend (T&E) regimen using aflibercept (Eylea) for diabetic macular edema (DME).Prospective, open-label, multicenter, single-arm, nonblinded clinical study.Forty eyes of 40 patients with DME received a T&E regimen of intravitreal aflibercept injection (IAI) with the longest treatment interval set to
Takao, Hirano, Yuichi, Toriyama, Yoshihiro, Takamura, Masahiko, Sugimoto, Taiji, Nagaoka, Yoshimi, Sugiura, Fumiki, Okamoto, Michiyuki, Saito, Kousuke, Noda, Shigeo, Yoshida, Akihiro, Ishibazawa, Osamu, Sawada, Toshinori, Murata   +12 more
openaire   +2 more sources

TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY

Retina, 2017
To investigate the efficacy of a treat-and-extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV).We retrospectively reviewed the medical records of 29 patients with PCV, who had been treated with a TER for 1 year. The primary outcome was the proportion of eyes that did not lose ≥3 best-corrected visual acuity (BCVA ...
Kang Yeun, Pak, Sung Who, Park, Ik Soo, Byon, Ji Eun, Lee   +3 more
openaire   +2 more sources

Treat and extend regimen for diabetic macular oedema—a systematic review and meta-analysis

Graefe's Archive for Clinical and Experimental Ophthalmology, 2022
Various treatment regimens are currently practiced in the treatment of CI-DMO (centre-involving diabetic macular oedema). In recent years, there has been a growing body of evidence supporting a treat and extend (T&E) regimen for DMO which offers the promise of comparable visual and anatomical outcomes while reducing injection burden. This meta-analysis
Sheng Yang Lim, Wendy Meihua Wong, Ivan Seah, Hwei Wuen Chan, Xinyi Su, Gopal Lingam, Yew Sen Yuen   +6 more
openaire   +2 more sources

Treat and extend versus PRN in diabetic retinopathy

Acta Ophthalmologica, 2016
SummaryVascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of the neo‐vascular age related macular degeneration (nAMD) and the ischemic retinal microangiopathies. Targeting VEGF in retinal diseases became an effective therapeutic option.To optimize the benefit of risk ratio and cost effectiveness of anti‐VEGF agents, a number
openaire   +1 more source

The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK

Advances in Therapy, 2016
Wet age-related macular degeneration (AMD) is a chronic eye condition that causes severe deterioration of vision and even blindness. Current wet AMD treatment in the UK involves the vascular endothelial growth factor inhibitors ranibizumab and aflibercept.
Wrik, Ghosh, Rose, Wickstead, Lindsay, Claxton, Jeanette, Kusel, Matthew, Taylor, Kelly, Fleetwood, Ruth, Pulikottil-Jacob   +6 more
openaire   +2 more sources

Monthly Versus Treat-and-Extend Ranibizumab for Diabetic Macular Edema: A Prospective, Randomized Trial

Ophthalmic Surgery, Lasers and Imaging Retina, 2018
BACKGROUND AND OBJECTIVE: Compare fixed monthly dosing of ranibizumab to treat-and-extend (T&E) ranibizumab during a period of 24 months for diabetic macular edema (DME) treatment. PATIENTS AND METHODS: Single-center, randomized, prospective pilot study that included 20 eyes of ...
David A, Eichenbaum, Emily, Duerr, Hershel R, Patel, Scott M, Pollack   +3 more
openaire   +2 more sources